News Headlines

31. Curium Strengthens Its PET Manufacturing Capacity And Expands European Footprint With The Acquisition Of Nucleis 4/10/2025

    Curium, a world leader in nuclear medicine, announced today that it has completed the acquisition of Nucleis, a specialist in GMP manufacturing and distribution of PET radiopharmaceutical drugs.

32. Novartis Plans To Expand Its US-Based Manufacturing And R&D Footprint With A Total Investment Of $23B Over The Next 5 Years 4/10/2025

    Today, Novartis, a leading global innovative medicines company, announced a planned $23 billion investment over 5 years in US-based infrastructure, ensuring all key Novartis medicines for US patients will be made in the United States.

33. Curium Enhances Its PET Manufacturing Capacity And Expands European Footprint With The Acquisition Of Nucleis 4/10/2025

    Curium, a world leader in nuclear medicine, announced today that it has completed the acquisition of Nucleis, a specialist in GMP manufacturing and distribution of PET radiopharmaceutical drugs.

34. Cellistic Launches Echo – NK Platform, A Scalable Solution For Off-The-Shelf Allogeneic Immune Cell Therapies 4/10/2025

    Cellistic, a pioneer in induced pluripotent stem cells (iPSC)-based cell therapies, is launching the Echo-NK platform to enable the scalable manufacturing of allogeneic cell therapies to target multiple diseases.

35. Ginkgo Bioworks Teams Up With Partners On ARPA-H Project To Stabilize Pharmaceutical Supply Chains - Using Amber Waves Of Grain 4/10/2025

    Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new contract with the Advanced Research Projects Agency for Health (ARPA-H), alongside partners Tritica Biosciences, US Pharmacopeia (USP), On Demand Pharmaceuticals, and Isolere Bio by Donaldson.

36. Cellares And University Of Wisconsin School Of Medicine And Public Health To Automate Clinical-Scale Production Of CRISPR-Edited CAR-T For Solid Tumors 4/10/2025

    Cellares, the pioneering Integrated Development and Manufacturing Organization (IDMO), has announced a strategic collaboration with the University of Wisconsin School of Medicine and Public Health to automate the manufacturing of a CRISPR-edited GD2 CAR-T investigational therapy.

37. Thermo Fisher Scientific, NSG BIO Collaborate To Strengthen Singapore's Biotech Startup Ecosystem 4/9/2025

    Thermo Fisher Scientific Inc, the world leader in serving science, has signed a strategic Memorandum of Understanding with NSG BIO, Singapore's largest BSL-2-certified, co-working laboratory and office space.

38. PharmaLogic To Acquire Majority Stake In Agilera, Strengthening Global Expertise In Radiopharmaceutical Therapeutics 4/9/2025

    PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specializing in radiopharmaceuticals, today announces that it will acquire a majority stake in Agilera Pharma AS ("Agilera") from the Institute for Energy Technology (IFE) in Norway, marking a significant step forward in the company's strategy to create the first fully-integrated, global CDMO specializing in radiopharmaceutical therapies.

39. Advancing Regional Polio Vaccine Production With Fixed-Bed Bioreactor Technology 4/9/2025

    Batavia Biosciences, a leading contract development and manufacturing organization (CDMO), has pioneered a novel upstream bioprocessing method to enhance regional polio vaccine production.

40. ArtBlood Signs MOU With Expression Manufacturing For Large-Scale In Vitro Red Blood Cell Production 4/8/2025

    ArtBlood, a biotechnology company specializing in transfusion blood production, announced that it has signed a Memorandum of Understanding (MOU) with Expression Manufacturing LLC ("Expression"), the manufacturing subsidiary of Expression Therapeutics, Inc., to collaborate on the clinical development and large-scale production of in vitro-produced blood.